Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks ...

Eli Lilly's experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight.

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst ...

Specializing in cutting-edge treatments like Semaglutide and Tirzepatide, Zest Meds has positioned itself as a leader in the weight loss industry. Their approach is simple yet effective ...

People claim the viral "natural Mounjaro" drink — honey, lemon, water, and ginger — makes you lose weight. Here's what an ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...